Egetis Therapeutics AB EGTX

First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United StatesEgetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® RareFDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval Egetis to host a conference call and webcast for analysts and investors on Tuesday September 29 at 8:00 am CEST (2:

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.